Skip to main content
David Scheinberg, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

DavidAScheinbergMD

Oncology • New York, NY

Professor of Medicine, Cornell University-Weill Medical College

Join to view full profile

Dr. Scheinberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Scheinberg's full profile

Already have an account?

Summary

  • David A. Scheinberg, M.D., Ph.D. is currently Vincent Astor Chair, and Chairman, Molecular Pharmacology, Sloan Kettering Institute. He also founded and Chairs the Center for Experimental Therapeutics, and founded and was Chair of the Nanotechnology Center from 2010 to 2014. He is additionally Professor of Medicine and Pharmacology and Co-chair of the Pharmacology graduate program at the Weill-Cornell Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSKCC. He is a founder and Director of the Therapeutics Discovery Institute, a non-profit drug discovery corporation formed with Weill Cornell Medical College, Rockefeller University and Sloan Kettering Institute; and founder and advisor to Bridge Medicines, a for-profit drug discovery corporation formed with the same three institutions. From 1992 until 2003, he was Chief of the Leukemia Service at Memorial Hospital. He has been elected into the American Society of Clinical Investigation (ASCI), the American Association of Physicians (AAP), and the Interurban Club. His other awards include the Doris Duke Distinguished Clinical Science Professorship, the Lucille P. Markey Scholarship, The Emil J. Freireich Award, Leukemia and Lymphoma Society Translational Investigator Awards, and CapCure Awards. In 2013, Nature Biotech recognized him as one of the top 20 Translational Scientists in the world. He is an advisor to charitable foundations and cancer centers and sits on the Boards of Directors of public and private biotech companies. Dr. Scheinberg is a physician-scientist, specializing in the care of patients with leukemia and also investigating new therapeutic approaches to cancer, both in the hospital and in the laboratory. The focus of his research is on the discovery and development of novel, specific immuno-therapeutic agents. This includes monoclonal antibodies that target cell surface or intracellular proteins of cancers and targeted radiopharmaceuticals.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1985 - 1987
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1983 - 1985
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1983

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1983 - 2026
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2001

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • MSK Research Highlights, February 23, 2023
    MSK Research Highlights, February 23, 2023February 23rd, 2023
  • Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80
    Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80June 6th, 2022
  • A Young Scientist Earns MSK Fellowship: Here’s When He Had His ‘Aha’ Moment
    A Young Scientist Earns MSK Fellowship: Here’s When He Had His ‘Aha’ MomentFebruary 10th, 2022
  • Join now to see all

Grant Support

  • Biology Of Alpha Particle ImmunotherapyNational Cancer Institute2009–2012
  • Potentiating & Focusing The Immune Response To Cancer By Use Of Peptide AntigensNational Cancer Institute2010–2011
  • Targeted Antigen Receptor Treatment Of CancerNational Cancer Institute2008–2009
  • Targeted Alpha-Particle TherapyNational Cancer Institute2008–2009
  • Potentiating &Focusing The Immune Response To Cancer By Use Of Peptide AntigensNational Cancer Institute2007–2009
  • Alpha-Particle Immunotherapy Of CancerNational Cancer Institute2004–2007
  • Leukemia Resistance Conferred By Marrow AllograftNational Cancer Institute2002
  • Clinical And Molecular Cancer Research Training ProgramNational Cancer Institute2001–2002
  • Radioimmunotherapy With Alpha And Beta EmittersNational Cancer Institute2000–2002
  • Recombinant Anticd33 Antibody For AMLNational Cancer Institute1999–2002
  • Potentiation Of Leukemia Resistance Conferred By Marrow AllograftNational Cancer Institute1997–2001
  • Immunotherapy Trials In LeukemiaNational Cancer Institute1996–1999
  • Recombinant Anti CD33 Antibody For AMLNational Cancer Institute1994–1997
  • Radioimmunotherapy In Chronic Myelogenous LeukemiaNational Cancer Institute1994–1995
  • Radioimmunotherapy In Chronic Myelogenous LeukemiaNational Cancer Institute1992–1993
  • Recombinant Anti-Cd33 Antibody For AMLNational Cancer Institute1991–1993

Hospital Affiliations

Dr. David Scheinberg, Dr. David Scheinberg, MD, Dr. D Scheinberg, Dr. David A Scheinberg